|Home | About | Journals | Submit | Contact Us | Français|
Mucosa‐associated lymphoid tissue (MALT) lymphoma is associated with recurrent chromosomal translocations t(11;18)(q21;q21), t(14;18)(q32;q21), t(1;14)(p22;q32) and t(3;14)(p14.1;q32).1,2 While t(11;18)(q21;q21) fuses the N‐terminus of the API2 (11q21) gene to the C‐terminus of the MALT1 (18q21) gene and generates a functional API2–MALT1 product, t(1;14)(p22;q32), t(14;18)(q32;q21) and t(3;14)(p14.1;q32) bring the BCL10(1p22), MALT1 (18q21) and FOXP1(3p14) genes, respectively, under the control of the immunoglobulin heavy chain (IGH, 14q32) enhancer, leading to their overexpression.1 Interestingly, the oncogenic activity of the first three chromosomal translocations is linked by the physiological role of BCL10 and MALT1 in antigen receptor‐mediated nuclear factor kappa B (NFκB) activation.1
Primary pulmonary MALT lymphomas show heterogeneous cytogenetic abnormalities, including aneuploidy and translocations. Among the translocations described in MALT lymphoma of this site, t(11;18)(q21;q21) is the most common, occurring in up to 50% of cases, and t(14;18)(q32;q21) and t(1;14)(p22;q32) are relatively rare.3,4,5 The overall incidence of t(1;14)(p22;q32) is approximately 3% in MALT lymphomas of different sites, and can be up to 10% in pulmonary cases.4,5,6 Recently, Achuthan et al7 reported t(1;2)(p22;p12) involving the BCL10 and the immunoglobulin kappa (IGK) light chain genes as a novel translocation in a gastric MALT lymphoma. Here we report the first case of pulmonary MALT lymphoma with this translocation, indicating that the t(1;2)(p22;p12) is a recurrent cytogenetic event in MALT lymphoma.
A 60‐year‐old Taiwanese lady presented with two abdominal wall masses for 1 month, and intermittent, productive cough for years. She was afebrile, without weight loss or night sweating. She was uraemic, with haemodialysis for 9 years, and had malignant fibrous histiocytoma (MFH) in the abdominal wall, with five excisions over the past 4 years. She had received transurethral resection of a high‐grade, transitional cell carcinoma of the bladder 4 months ago. Physical examination revealed protruding masses at the left abdominal wall and left flank (8 cm each), without lymphadenopathy. Her haemoglobin was 11.2 g/dl; leucocyte and platelet counts and lactate dehydrogenase (LDH) level were normal. Her serum was positive for hepatitis B surface antigen (HBsAg) and anti‐hepatitis C virus (HCV) and negative for anti‐human immunodeficiency virus (HIV). Chest x ray revealed a few nodules in the right upper lung and was confirmed by CT scan without lymphadenopathy or splenomegaly. CT‐guided biopsy of the largest tumour (3.6 cm) revealed MALT lymphoma. Marrow biopsy was not performed. She did not receive chemotherapy or radiotherapy. Excision of the abdominal tumours 1 month later revealed recurrent MFH with mesocolonic metastasis. After 5 months, multiple pulmonary masses up to 10 cm were noted in the right lung, and CT‐guided biopsy revealed metastatic MFH, which had probably over‐run the MALT lymphoma.
Microscopically, the first pulmonary needle biopsy showed total effacement of pulmonary parenchyma by a diffuse infiltrate of atypical small lymphocytes with three colonised follicles. These atypical lymphocytes exhibited twisted nuclei, with focal plasmacytic differentiation and some intranuclear Dutcher bodies (fig 1A1A).). These atypical lymphocytes expressed CD20, CD27, CD43, IgM, BCL2 and strong nuclear BCL10 (fig 1B1B)8 but not CD3, CD5, CD10, CD23, IgD or BCL6, and were monotypic for λ light chain. The diagnosis of pulmonary MALT lymphoma was made.
Reverse transcription‐PCR for API2–MALT fusion transcripts using paraffin‐wax sections, as described previously, was negative.9 Fluorescence in situ hybridisation (FISH) studies using paraffin‐wax sections with IGH, BCL6 and MALT1 dual‐colour break‐apart rearrangement probes (Vysis/Abbott Laboratories. Maidenhead, Berkshire, UK) were negative; however, three copies of the MALT1 and BCL6 genes were identified in 73% and 45% of cells, respectively, suggesting the presence of trisomies 18 and 3. The latter was confirmed by FISH with chromosome enumeration probes for chromosomes 18 and 3 (Vysis/Abbott). Further FISH experiments with BCL10 and IGK locus dual‐colour break‐apart rearrangement probes were both positive in 78% and 75% cells, respectively (fig 1C,D1C,D).5,10 t(1;2)(p22;p12)/IGK‐BCL10 was confirmed by using IGK‐BCL10 dual‐colour dual‐fusion translocation probes (fig 1E1E).5,10 As t(1;14)(p22;q32)‐associated MALT lymphoma was reported to involve recurrent trisomy 12,11 FISH with a probe for centromere 12 (Vysis/Abbott) was also performed, and showed trisomy 12 in this case.
The BCL10 gene‐involved translocation occurs in approximately 3% of MALT lymphomas.5 The translocation is described primarily in those from the stomach and lung and commonly involves the IGH locus at 14q32, resulting in overexpression of BCL10.5,6,8 Consequently, strong BCL10 expression in the nuclei of lymphoma cells has been invariably demonstrated in all the translocation‐positive cases immunostained for BCL10.5,6,8 This is in contrast with nearly all t(11;18)(q21;q21)‐positive MALT lymphomas and up to 20% of cases without t(11;18)(q21;q21), where BCL10 shows a moderate level of nuclear expression, and with other MALT lymphomas and normal germinal centre B cells where BCL10 is expressed weakly in the cytoplasm. Therefore, a strong nuclear BCL10 staining pattern in MALT lymphoma has been suggested as a marker of t(1;14)(p22;q32).5,8,12 Furthermore, BCL10 has been found to be expressed at high level in the nuclei of splenic marginal‐zone B cells in transgenic mice in which BCL10 gene expression was driven by IGH enhancers.13 The mechanism of transportation of BCL10 from the cytoplasm to the nucleus and how it contributes to lymphoma development is still unclear. However, the deregulated expression of BCL10 resulting from translocation is undoubtedly important in MALT lymphomagenesis. Studies have shown that BCL10 is a molecule essential for NFκB activation by antigen receptor stimulation in both the development and function of lymphocytes, and that NFκB activation may contribute to the antiapoptotic effect.14,15
Translocations involving the IGK or IGL loci represent 5–10% of all IG translocations in lymphoid malignancies.16 Achuthan et al7 reported a novel t(1;2)(p22;p12)/BCL10‐IGK in a gastric MALT lymphoma without information on BCL10 expression. Our case is the first pulmonary MALT lymphoma with this translocation, and shows strong nuclear BCL10 expression. Our finding confirms that BCL10 is upregulated in t(1;2)(p22;p12) as well as in t(1;14)(p22;q32), and strong nuclear BCL10 staining is highly suggestive of the presence of BCL10‐involved translocation. Like t(1;14)(p22;q32), which is mutually exclusive from t(11;18)(q21;q21) and t(14;18)(q32;q21), but may display additional genomic abnormalities, our present t(1;2)(p22;p12)‐positive case did not carry IGH, API2, MALT1 or BCL6 translocations, but showed trisomies 3, 12 and 18, which are typical secondary aberrations in t(1;14)‐positive MALT lymphomas.11 Recognition of this translocation is important, as it might constitute a specific clinicopathological subtype among MALT lymphomas, which usually presents at a more advanced stage and, if arising in the stomach, does not respond to Helicobacter pylori eradication.12
In conclusion, our case is the first pulmonary MALT lymphoma carrying t(1;2)(p22;p12)/IGK‐BCL10, indicating that the t(1;2)(p22;p12) is a recurrent cytogenetic event in MALT lymphoma.
This study was supported by research grants from the Leukaemia Research Fund, UK, and Deutsche Krebshilfe.
Competing interests: None declared.